{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T05:47:41Z","timestamp":1790833661230,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd006687.pub3","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T00:00:00Z","timestamp":1621209600000}}],"reference-count":126,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd006687.pub4","type":"journal-article","created":{"date-parts":[[2021,5,17]],"date-time":"2021-05-17T07:45:02Z","timestamp":1621237502000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Vasodilators for primary Raynaud's phenomenon"],"prefix":"10.1002","volume":"2021","author":[{"given":"Kevin YC","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Rheumatology; Gold Coast University Hospital; Southport Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghna","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Rheumatology; Gold Coast University Hospital; Southport Australia"},{"name":"School of Medicine; Bond University; Robina Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyunjun Jonathan","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Rheumatology; Gold Coast University Hospital; Southport Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Kaganov","sequence":"additional","affiliation":[{"name":"Department of Rheumatology; Gold Coast University Hospital; Southport Australia"},{"name":"School of Medicine; Bond University; Robina Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Hughes","sequence":"additional","affiliation":[{"name":"Office for Research Governance and Development; Gold Coast University Hospital; Southport Australia"},{"name":"School of Medicine, The University of Queensland; St Lucia Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed Hashim","family":"Abdeen","sequence":"additional","affiliation":[{"name":"Department of Rheumatology; Gold Coast University Hospital; Southport Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer Hwee Kwoon","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Rheumatology; Gold Coast University Hospital; Southport Australia"},{"name":"School of Medicine; Griffith University, Gold Coast Campus; Southport Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,5,17]]},"reference":[{"issue":"15","key":"10.1002\/14651858.CD006687.pub4-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1001\/archinternmed.2012.2271","article-title":"Vardenafil for the treatment of Raynaud phenomenon: a randomized, double-blind, placebo-controlled crossover study","volume":"172","author":"Caglayan","year":"2012","journal-title":"Archives of Internal Medicine"},{"issue":"6","key":"10.1002\/14651858.CD006687.pub4-BIB0002|cit2","first-page":"739P","article-title":"Clinical and physiological assessment of angiotensin-converting enzyme inhibition in primary Raynaud's phenomenon","volume":"28","author":"Challenor","year":"1989","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD006687.pub4-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2125.1991.tb05565.x","article-title":"Subjective and objective assessment of enalapril in primary Raynaud's phenomenon","volume":"31","author":"Challenor","year":"1991","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"3","key":"10.1002\/14651858.CD006687.pub4-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1002\/art.24351","article-title":"MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial","volume":"60","author":"Chung","year":"2009","journal-title":"Arthritis and Rheumatism"},{"key":"10.1002\/14651858.CD006687.pub4-BIB0005|cit5","unstructured":"Phase III study of topical gel for treatment and prevention of Raynaud's phenomenon clinicaltrials.gov\/show\/NCT00266669"},{"issue":"3","key":"10.1002\/14651858.CD006687.pub4-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/0002-9343(84)90101-3","article-title":"Controlled double-blind trial of dazoxiben and nifedipine in the treatment of Raynaud's phenomenon","volume":"77","author":"Ettinger","year":"1984","journal-title":"American Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006687.pub4-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/0002-9343(85)90402-4","article-title":"Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation","volume":"78","author":"Malamet","year":"1984","journal-title":"American Journal of Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006687.pub4-BIB0008|cit8","first-page":"751","article-title":"Reproducibility of cold provocation in patients with Raynaud's phenomenon","volume":"14","author":"Wigley","year":"1987","journal-title":"Journal of Rheumatology"},{"issue":"11-12","key":"10.1002\/14651858.CD006687.pub4-BIB0009|cit9","first-page":"343","article-title":"Thymoxamine for Raynaud's disease and chilblains","volume":"34","author":"Jaffe","year":"1980","journal-title":"British Journal of Clinical Practice"},{"issue":"4","key":"10.1002\/14651858.CD006687.pub4-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/000331979104200405","article-title":"Double-blind placebo-controlled trial of buflomedil in the treatment of Raynaud's phenomenon: six-month follow-up","volume":"42","author":"Le Quentrec","year":"1991","journal-title":"Angiology"},{"issue":"36","key":"10.1002\/14651858.CD006687.pub4-BIB0011|cit11","first-page":"2695","article-title":"[Raynaud's disease treated with captopril (Capoten). A randomized double-blind cross-over study]","volume":"146","author":"Madsen","year":"1984","journal-title":"Ugeskrift for Laeger"},{"issue":"2","key":"10.1002\/14651858.CD006687.pub4-BIB0012|cit12","first-page":"139","article-title":"Double-blind randomized trial of Nitroderm TTS in the treatment of raynaud's phenomenon","volume":"22","author":"Nahir","journal-title":"Israel Journal of Medical Sciences"},{"key":"10.1002\/14651858.CD006687.pub4-BIB0013|cit13","unstructured":"PF-00489791 for the treatment of Raynaud's clinicaltrials.gov\/show\/NCT01090492"},{"issue":"11","key":"10.1002\/14651858.CD006687.pub4-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1016\/j.amjcard.2003.08.013","article-title":"Effects of cilostazol in patients with Raynaud's syndrome","volume":"92","author":"Rajagopalan","year":"2003","journal-title":"American Journal of Cardiology"},{"issue":"6","key":"10.1002\/14651858.CD006687.pub4-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1111\/j.1365-2133.1987.tb07356.x","article-title":"The effect of captopril on cutaneous blood flow in patients with primary Raynaud's phenomenon","volume":"117","author":"Rustin","year":"1987","journal-title":"British Journal of Dermatology"},{"issue":"5","key":"10.1002\/14651858.CD006687.pub4-BIB0016|cit16","first-page":"832","article-title":"Transdermal nitroglycerin in the treatment of Raynaud's phenomenon: analysis of digital blood pressure changes after cold provocation","volume":"35","author":"Sovijarvi","year":"1984","journal-title":"Current Therapeutic Research - Clinical and Experimental"},{"issue":"7","key":"10.1002\/14651858.CD006687.pub4-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1093\/rheumatology\/34.7.636","article-title":"Sustained-release transdermal glyceryl trinitrate patches as a treatment for primary and secondary Raynaud's phenomenon","volume":"34","author":"O'Reilly","year":"1995","journal-title":"British Journal of Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD006687.pub4-BIB0018|cit18","first-page":"657","article-title":"Quantitative study of the effects of Ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled investigation and an additional long term open trial","volume":"2","author":"de Wal","year":"1985","journal-title":"Microcirculation, Endothelium and Lymphatics"},{"issue":"3","key":"10.1002\/14651858.CD006687.pub4-BIB0019|cit19","first-page":"313","article-title":"The effectiveness of ketanserin in patients with primary Raynaud's phenomenon. A randomized, double blind, placebo controlled study","volume":"6","author":"de Wal","year":"1987","journal-title":"International Angiology"},{"issue":"11","key":"10.1002\/14651858.CD006687.pub4-BIB0020|cit20","first-page":"1917","article-title":"Controlled multicenter double blind trial of an oral analog of prostacyclin in the treatment of primary Raynaud's phenomenon. French Microcirculation Society Multicentre Group for the Study of Vascular Acrosyndromes","volume":"23","author":"Vayssairat","year":"1996","journal-title":"Journal of Rheumatology"},{"issue":"9","key":"10.1002\/14651858.CD006687.pub4-BIB0021|cit21","first-page":"465","article-title":"[Pharmacotherapy of Raynaud's phenomenon]","volume":"31","author":"Allegra","year":"1983","journal-title":"Minerva Cardioangiologica"},{"issue":"2","key":"10.1002\/14651858.CD006687.pub4-BIB0022|cit22","first-page":"260","article-title":"[Intra-arterial reserpine in Raynaud's disease and syndrome]","volume":"42","author":"Arcas Meca","year":"1972","journal-title":"Archivos del Instituto de Cardiologi\u0301a de Me\u0301xico"},{"issue":"1","key":"10.1002\/14651858.CD006687.pub4-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1177\/000331977802900107","article-title":"Pathophysiology of capillary circulation: Raynaud's disease","volume":"29","author":"Arnot","year":"1978","journal-title":"Angiology"},{"issue":"7","key":"10.1002\/14651858.CD006687.pub4-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1177\/000331978904000705","article-title":"Comparative efficacy of ketanserin and pentoxiphylline in treatment of Raynaud's phenomenon","volume":"40","author":"Arosio","year":"1989","journal-title":"Angiology"},{"issue":"1","key":"10.1002\/14651858.CD006687.pub4-BIB0025|cit25","first-page":"13","article-title":"Discontinuing long-term Iloprost treatment for Raynaud's phenomenon and systemic sclerosis: a single-center, randomized, placebo-controlled, double-blind study","volume":"20","author":"Bali","year":"2011","journal-title":"Acta Dermatovenerologica Alpina, Panonica et Adriatica"},{"issue":"4","key":"10.1002\/14651858.CD006687.pub4-BIB0026|cit26","first-page":"7","article-title":"Does losartan improve short-term symptoms of Reynaud's phenomenon?","volume":"3","author":"Barry","year":"2000","journal-title":"Evidence-Based Practice"},{"issue":"8320","key":"10.1002\/14651858.CD006687.pub4-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0140-6736(83)91624-0","article-title":"Intermittent epoprostenol (prostacyclin) infusion in patients with Raynaud's syndrome. A double-blind controlled trial","volume":"1","author":"Belch","year":"1983","journal-title":"Lancet"},{"issue":"8439","key":"10.1002\/14651858.CD006687.pub4-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/S0140-6736(85)92862-4","article-title":"Double-blind trial of CL115,347, a transdermally absorbed prostaglandin E2 analogue, in treatment of Raynaud's phenomenon","volume":"1","author":"Belch","year":"1985","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD006687.pub4-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/ard.54.3.197","article-title":"Oral iloprost as a treatment for Raynaud's syndrome: a double blind multicentre placebo controlled study","volume":"54","author":"Belch","year":"1995","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"27","key":"10.1002\/14651858.CD006687.pub4-BIB0030|cit30","first-page":"1335","article-title":"[Treatment of Raynaud's syndrome with ketanserin. Clinical, biological and hemodynamic aspects]","volume":"16","author":"Bellucci","year":"1987","journal-title":"Presse Medicale"},{"key":"10.1002\/14651858.CD006687.pub4-BIB0031|cit31","first-page":"524","article-title":"[Treatment for Raynaud's syndrome using infusions of iloprost. A controlled prospective trial]","volume":"45","author":"Belluci","year":"1990","journal-title":"Therapie"},{"issue":"6","key":"10.1002\/14651858.CD006687.pub4-BIB0032|cit32","first-page":"767","article-title":"The importance of presynaptic beta receptors in Raynaud's disease","volume":"9","author":"Brotzu","year":"1989","journal-title":"Journal of Vascular Surgery"},{"issue":"3-4","key":"10.1002\/14651858.CD006687.pub4-BIB0033|cit33","first-page":"164","article-title":"Studies on the effect of alpha- and of beta-adrenergic blocking agents on the circulation in human limbs","volume":"42","author":"Clement","year":"1980","journal-title":"Verhandelingen Van De Koninklijke Academie voor Geneeskunde van Belgie"},{"issue":"Suppl.2","key":"10.1002\/14651858.CD006687.pub4-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"S84","DOI":"10.1097\/00005344-198600082-00018","article-title":"Effect of indoramin on finger circulation in patients with Raynaud disease","volume":"8","author":"Clement","year":"1986","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"11","key":"10.1002\/14651858.CD006687.pub4-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1177\/000331978403501105","article-title":"Therapeutic efficacy of alpha-adrenoceptor blockade in primary and secondary Raynaud's syndrome","volume":"35","author":"Cleophas","year":"1984","journal-title":"Angiology"},{"issue":"1","key":"10.1002\/14651858.CD006687.pub4-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1177\/000331978403500104","article-title":"Treatment of Raynaud's syndrome with adrenergic alpha-blockade with or without beta-blockade","volume":"35","author":"Cleophas","year":"1984","journal-title":"Angiology"},{"issue":"3","key":"10.1002\/14651858.CD006687.pub4-BIB0037|cit37","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/S0002-9343(89)80148-2","article-title":"International study of ketanserin in Raynaud's phenomenon","volume":"87","author":"Coffman","year":"1989","journal-title":"American Journal of Medicine"},{"issue":"9","key":"10.1002\/14651858.CD006687.pub4-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/rheumatology\/40.9.1038","article-title":"Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine","volume":"40","author":"Coleiro","year":"2001","journal-title":"Rheumatology"},{"issue":"10","key":"10.1002\/14651858.CD006687.pub4-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1177\/000331978103201002","article-title":"Double-blind capillaroscopic study of the activity of buflomedil in Raynaud's syndrome: a report on 80 cases","volume":"32","author":"Courbier","year":"1981","journal-title":"Angiology"},{"issue":"4","key":"10.1002\/14651858.CD006687.pub4-BIB0040|cit40","first-page":"147","article-title":"Double blind capillaroscopic study of buflomedil effect in Raynaud's phenomenon. [French]","volume":"33","author":"Courbier","year":"1981","journal-title":"Angiology"},{"issue":"36","key":"10.1002\/14651858.CD006687.pub4-BIB0041|cit41","first-page":"1322","article-title":"Double-blind clinical evaluation of naftidrofuryl in Raynaud's phenomenon","volume":"69","author":"Davinroy","year":"1993","journal-title":"Semaine des Hopitaux"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD006687.pub4-BIB0042|cit42","first-page":"185","article-title":"Isosorbide dinitrate ointment in Raynaud's disease","volume":"73","author":"Diehm","year":"1983","journal-title":"Zeitschrift fu\u0308r Kardiologie"},{"issue":"4","key":"10.1002\/14651858.CD006687.pub4-BIB0043|cit43","first-page":"168","article-title":"Trial of a new drug in Raynaud's disease. Clinical and thermographic control","volume":"18","author":"Dumoulin","year":"1981","journal-title":"Electrodiagnostic Therapie"},{"issue":"12","key":"10.1002\/14651858.CD006687.pub4-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T","article-title":"Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial","volume":"42","author":"Dziadzio","year":"1999","journal-title":"Arthritis and Rheumatism"},{"issue":"5","key":"10.1002\/14651858.CD006687.pub4-BIB0045|cit45","first-page":"298","article-title":"Topical nitroglycerin ointment in Raynaud's phenomenon","volume":"74","author":"Fischer","year":"1985","journal-title":"Zeitschrift fu\u0308r Kardiologie"},{"issue":"4","key":"10.1002\/14651858.CD006687.pub4-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/sj.clpt.6100103","article-title":"The effects of tadalafil on cold-induced vasoconstriction in patients with Raynaud's phenomenon","volume":"81","author":"Friedman","year":"2007","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD006687.pub4-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0950-821X(89)80066-0","article-title":"The efficacy of thymoxamine in primary Raynaud's phenomenon","volume":"3","author":"Grigg","year":"1989","journal-title":"European Journal of Vascular Surgery"},{"issue":"2","key":"10.1002\/14651858.CD006687.pub4-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1365-2710.1988.tb00171.x","article-title":"Enalapril in Raynaud's phenomenon","volume":"13","author":"Janini","year":"1988","journal-title":"Journal of Clincal Pharmacy and Therapeutics"},{"issue":"5","key":"10.1002\/14651858.CD006687.pub4-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/j.jaad.2013.06.029","article-title":"A pilot study evaluating the efficacy of botulinum toxin A in the treatment of Raynaud phenomenon","volume":"69","author":"Jenkins","year":"2013","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"8","key":"10.1002\/14651858.CD006687.pub4-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/oxfordjournals.eurheartj.a061923","article-title":"Nifedipine and alpha 1-adrenergic blockade in Raynaud's phenomenon","volume":"6","author":"Kahan","year":"1985","journal-title":"European Heart Journal"},{"issue":"3","key":"10.1002\/14651858.CD006687.pub4-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1097\/00005344-199509000-00007","article-title":"Double-blind, placebo-controlled study of intravenous prostacyclin on hemodynamics in severe Raynaud's phenomenon: the acute vasodilatory effect is not sustained","volume":"26","author":"Kingma","year":"1995","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"11","key":"10.1002\/14651858.CD006687.pub4-BIB0052|cit52","first-page":"40","article-title":"[A new peripheral vasodilator prostaglandin E1 in atherosclerosis of lower limb vessels and Raynaud disease]","volume":"69","author":"Kirichenko","year":"1991","journal-title":"Klinicheskaia Meditsina"},{"issue":"9","key":"10.1002\/14651858.CD006687.pub4-BIB0053|cit53","first-page":"1403","article-title":"Placebo controlled study showing therapeutic benefit of iloprost in the treatment of Raynaud's phenomenon","volume":"19","author":"Kyle","year":"1992","journal-title":"Journal of Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD006687.pub4-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/rheumatology\/ket417","article-title":"Head-to-head comparison of udenafil vs amlodipine in the treatment of secondary Raynaud's phenomenon: a double-blind, randomized, cross-over study","volume":"53","author":"Lee","year":"2014","journal-title":"Rheumatology"},{"issue":"Suppl.7","key":"10.1002\/14651858.CD006687.pub4-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1097\/00005344-198500077-00028","article-title":"Effects of ketanserin on peripheral blood flow, haemorheology, and platelet function in patients with Raynaud's phenomenon","volume":"7","author":"Longstaff","year":"1985","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"1","key":"10.1002\/14651858.CD006687.pub4-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/clpt.1984.147","article-title":"Dazoxiben, a thromboxane synthetase inhibitor, in Raynaud's phenomenon","volume":"36","author":"Luderer","year":"1984","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD006687.pub4-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/BF00561375","article-title":"Ketanserin treatment and serotonin in patients with primary and secondary Raynaud's phenomenon","volume":"35","author":"Marasini","year":"1988","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"4","key":"10.1002\/14651858.CD006687.pub4-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/03009740310004711","article-title":"Comparison between iloprost and alprostadil in the treatment of Raynaud's phenomenon","volume":"33","author":"Marasini","year":"2004","journal-title":"Scandinavian Journal of Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD006687.pub4-BIB0059|cit59","first-page":"127","article-title":"Action of buflomedil on the cutaneous microcirculation studied by a cold provocation test. Multicentre double-blind placebo controlled trial","volume":"20","author":"Maurel","year":"1995","journal-title":"Journal des Maladies Vasculaires"},{"issue":"4","key":"10.1002\/14651858.CD006687.pub4-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1001\/archinte.1973.03650100044008","article-title":"Intra-arterial reserpine administration in Raynaud syndrome","volume":"132","author":"McFadyen","year":"1973","journal-title":"Archives of Internal Medicine"},{"issue":"4","key":"10.1002\/14651858.CD006687.pub4-BIB0061|cit61","first-page":"JC21","article-title":"In Raynaud phenomenon, on-demand sildenafil did not reduce disability or frequency or duration of attacks","volume":"170","author":"Mirza","year":"2019","journal-title":"ACP Journal Club 2019, Pennsylvania American College of Physicians 2019"},{"issue":"11","key":"10.1002\/14651858.CD006687.pub4-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1136\/ard.44.11.754","article-title":"A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud's syndrome","volume":"44","author":"Mohrland","year":"1985","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1002\/14651858.CD006687.pub4-BIB0063|cit63","unstructured":"Safety and efficacy of pletal (cilostazol) for the treatment of juvenile primary and secondary Raynaud\u2019s phenomenon clinicaltrials.gov\/ct2\/show\/NCT00048763"},{"key":"10.1002\/14651858.CD006687.pub4-BIB0064|cit64","unstructured":"Phase III study of a topical gel formulation for treatment and prevention of Raynaud's phenomenon clinicaltrials.gov\/ct2\/show\/NCT00419419"},{"key":"10.1002\/14651858.CD006687.pub4-BIB0065|cit65","unstructured":"Safety and efficacy of pletal (cilostazol) for the treatment of juvenile primary and secondary Raynaud\u2019s phenomenon clinicaltrials.gov\/ct2\/show\/NCT00048776"},{"key":"10.1002\/14651858.CD006687.pub4-BIB0066|cit66","unstructured":"Botulinum toxin in the treatment of Raynaud's https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01233999"},{"issue":"3","key":"10.1002\/14651858.CD006687.pub4-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/BF00610065","article-title":"Prazosin treatment of primary Raynaud's phenomenon","volume":"24","author":"Nielsen","year":"1983","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"6155","key":"10.1002\/14651858.CD006687.pub4-BIB0068|cit68","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1136\/bmj.1.6155.20-a","article-title":"Effects of naftidrofuryl on microcirculatory cold sensitivity in Raynaud's phenomenon","volume":"1","author":"Nilsen","year":"1979","journal-title":"British Medical Journal"},{"issue":"8 Suppl 1","key":"10.1002\/14651858.CD006687.pub4-BIB0069|cit69","first-page":"e4","article-title":"On demand sildenafil as a treatment of raynaud's phenomenon: a series of n-of-1 trials","volume":"39","author":"Roustit","year":"2017","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD006687.pub4-BIB0070|cit70","first-page":"94","article-title":"Prazosin treatment of Raynaud's phenomenon: a double blind single crossover study","volume":"12","author":"Russell","year":"1985","journal-title":"Journal of Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD006687.pub4-BIB0071|cit71","first-page":"337","article-title":"Selective antagonism of S2-serotonergic receptors relieves but does not prevent cold induced vasoconstriction in primary Raynaud's phenomenon","volume":"13","author":"Seibold","year":"1986","journal-title":"Journal of Rheumatology"},{"key":"10.1002\/14651858.CD006687.pub4-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2125.1991.tb03883.x","article-title":"Prolonged effect of CGRP in Raynaud's patients: a double-blind randomised comparison with prostacyclin","volume":"32","author":"Shawket","year":"1991","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1002\/14651858.CD006687.pub4-BIB0073|cit73","first-page":"14","article-title":"Captopril therapy of Raynaud's syndrome","volume":"Issue 1","author":"Shcherbakov","year":"1992","journal-title":"Revmatologiia"},{"issue":"2","key":"10.1002\/14651858.CD006687.pub4-BIB0074|cit74","first-page":"225","article-title":"Management of Raynaud's phenomenon with drugs affecting the sympathetic nervous system. A double-blind crossover study","volume":"32","author":"Strozzi","year":"1982","journal-title":"Current Theraputic Research"},{"issue":"1","key":"10.1002\/14651858.CD006687.pub4-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1007\/BF02284056","article-title":"A double blind randomised placebo controlled trial of hexopal in primary Raynaud's disease","volume":"7","author":"Sunderland","year":"1988","journal-title":"Clinical Rheumatology"},{"issue":"4","key":"10.1002\/14651858.CD006687.pub4-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/BF00998892","article-title":"The combined effect of prazosin and autogenic training on cold reactivity in Raynaud's phenomenon","volume":"7","author":"Surwit","year":"1982","journal-title":"Biofeedback and Self-regulation"},{"issue":"3","key":"10.1002\/14651858.CD006687.pub4-BIB0077|cit77","first-page":"249","article-title":"Ketanserin and capillary flow in Raynaud's phenomenon","volume":"9","author":"Tooke","year":"1990","journal-title":"International Journal of Microcirculation-Clinical and Experimental"},{"key":"10.1002\/14651858.CD006687.pub4-BIB0078|cit78","doi-asserted-by":"crossref","unstructured":"Tooke JE Williams SA Rawlinson DW Black C The effects of ketanserin on capillary flow in Raynaud's phenomenon Clinical Science 1987 17 74P","DOI":"10.1042\/cs072074Pb"},{"issue":"5","key":"10.1002\/14651858.CD006687.pub4-BIB0079|cit79","first-page":"157","article-title":"A double blind randomised comparison of two doses of iloprost in the treatment of Raynauds phenomenon","volume":"35","author":"Torley","year":"1990","journal-title":"Scottish Medical Journal"},{"issue":"9191","key":"10.1002\/14651858.CD006687.pub4-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(99)04095-7","article-title":"Effect of nitric-oxide-generating system on microcirculatory blood flow in skin of patients with severe Raynaud's syndrome: a randomised trial","volume":"354","author":"Tucker","year":"1999","journal-title":"Lancet"},{"issue":"5","key":"10.1002\/14651858.CD006687.pub4-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/BF00615400","article-title":"Sublingual and oral isoxsuprine in patients with Raynaud's phenomenon","volume":"20","author":"Wesseling","year":"1981","journal-title":"European Journal of Clinical Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD006687.pub4-BIB0082|cit82","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/clpt.1986.166","article-title":"Double-blind, placebo-controlled study of prazosin in Raynaud's phenomenon","volume":"40","author":"Wollersheim","year":"1986","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"10.1002\/14651858.CD006687.pub4-BIB0083|cit83","first-page":"234","article-title":"Evaluation of the efficacy of beraprost sodium (PGI2 analogue) for Raynaud's disease and Raynaud's syndrome: a double-blind placebo-controlled study","volume":"67","author":"Sakaguchi","year":"1990","journal-title":"Rinsho to Kenkyu"},{"key":"10.1002\/14651858.CD006687.pub4-BIB0084|cit84","unstructured":"Double-blind,placebo-controlled cross-over study for evaluation of the efficacy of the PDE-5-inhibitor vardenafil on the peripheral perfusion and the clinical symptomatology of patients with Raynaud's disease who.int\/trialsearch\/Trial2.aspx?TrialID=EUCTR2005-000295-41-DE"},{"key":"10.1002\/14651858.CD006687.pub4-BIB0085|cit85","unstructured":"Assess efficacy of oral treprostinil in patients with symptomatic primary or secondary Raynaud's phenomenon clinicaltrials.gov\/ct2\/show\/study\/NCT02583789"},{"issue":"19","key":"10.1002\/14651858.CD006687.pub4-BIB0086|cit86","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1056\/NEJM199911043411907","article-title":"Calcium-antagonist drugs","volume":"341","author":"Abernethy","year":"1999","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD006687.pub4-BIB0087|cit87","unstructured":"Australian Medicines Handbook 2020 (online) amhonline.amh.net.au\/"},{"key":"10.1002\/14651858.CD006687.pub4-BIB0088|cit88","unstructured":"Anatomical Therapeutical Chemical Classification, WHO whocc.no\/atcddd"},{"issue":"7454","key":"10.1002\/14651858.CD006687.pub4-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.328.7454.1490","article-title":"Grading quality of evidence and strength of recommendations","volume":"328","author":"Atkins","year":"2004","journal-title":"British Medical Journal"},{"issue":"4","key":"10.1002\/14651858.CD006687.pub4-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.jaad.2008.06.004","article-title":"Raynaud\u2019s phenomenon: pathogenesis and management","volume":"59","author":"Bakst","year":"2008","journal-title":"Journal of the American Academy of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD006687.pub4-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/rheumatology\/29.3.162","article-title":"The phenomenon, syndrome and disease of Maurice Raynaud","volume":"29","author":"Belch","year":"1990","journal-title":"British Journal of Rheumatology"},{"issue":"9273","key":"10.1002\/14651858.CD006687.pub4-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1016\/S0140-6736(00)05118-7","article-title":"Raynaud's phenomenon","volume":"357","author":"Block","year":"2001","journal-title":"Lancet"},{"issue":"4","key":"10.1002\/14651858.CD006687.pub4-BIB0093|cit93","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/0049-0172(81)90006-8","article-title":"Raynaud's syndrome","volume":"10","author":"Blunt","year":"1981","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"9","key":"10.1002\/14651858.CD006687.pub4-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1093\/rheumatology\/40.9.1038","article-title":"Treatment of Raynaud's phenomenon with the selective serotonin reuptake inhibitor fluoxetine","volume":"40","author":"Coleiro","year":"2001","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD006687.pub4-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"c869","DOI":"10.1136\/bmj.c869","article-title":"CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Moher","year":"2010","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD006687.pub4-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1191\/1358863x05vm639ra","article-title":"Mechanisms of Raynaud's disease","volume":"10","author":"Cooke","year":"2005","journal-title":"Vascular Medicine"},{"issue":"15","key":"10.1002\/14651858.CD006687.pub4-BIB0097|cit97","first-page":"2131","article-title":"Meta-analysis combining parallel and cross-over clinical trials. I: continuous outcomes","volume":"21","author":"Curtin","year":"2002","journal-title":"Statistical Methodology"},{"issue":"3","key":"10.1002\/14651858.CD006687.pub4-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Controlled Clinical Trials"},{"issue":"4","key":"10.1002\/14651858.CD006687.pub4-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00393-006-0068-x","article-title":"[Evidence-based therapy of Raynaud's syndrome]","volume":"65","author":"Distler","year":"2006","journal-title":"Zeitschrift fur Rheumatologie"},{"issue":"3","key":"10.1002\/14651858.CD006687.pub4-BIB0100|cit100","doi-asserted-by":"publisher","first-page":"10.2217\/fca.13.","DOI":"10.2217\/fca.13.6","article-title":"Pharmacologic treatments for pulmonary hypertension: exploring pharmacogenomics","volume":"9","author":"Duarte","year":"2013","journal-title":"Future Cardiology"},{"issue":"12","key":"10.1002\/14651858.CD006687.pub4-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T","article-title":"Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial","volume":"42","author":"Dziadzio","year":"1999","journal-title":"Arthritis and Rheumatism"},{"issue":"1","key":"10.1002\/14651858.CD006687.pub4-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD006687.pub4-BIB0103|cit103","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002069.pub5","article-title":"Calcium channel blockers for primary Raynaud's phenomenon","author":"Ennis","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD006687.pub4-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"e006389","DOI":"10.1136\/bmjopen-2014-006389","article-title":"Prevalence, risk factors and associations of primary Raynaud's phenomenon: systematic review and meta-analysis of observational studies","volume":"5","author":"Garner","year":"2015","journal-title":"BMJ Open"},{"key":"10.1002\/14651858.CD006687.pub4-BIB0105|cit105","unstructured":"McMaster University (developed by Evidence Prime) GRADEpro GDT 2015"},{"issue":"4","key":"10.1002\/14651858.CD006687.pub4-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0950-821X(89)80066-0","article-title":"The efficacy of thymoxamine in primary Raynaud's phenomenon","volume":"3","author":"Grigg","year":"1989","journal-title":"European Journal of Vascular Surgery"},{"issue":"5","key":"10.1002\/14651858.CD006687.pub4-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"587-96","DOI":"10.1093\/rheumatology\/keh552","article-title":"Pathogenesis of Raynaud's phenomenon","volume":"44","author":"Herrick","year":"2005","journal-title":"Rheumatology"},{"key":"10.1002\/14651858.CD006687.pub4-BIB0108|cit108","unstructured":"Higgins JP Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD006687.pub4-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/j.berh.2016.04.001","article-title":"Raynaud's phenomenon","volume":"30","author":"Hughes","year":"2016","journal-title":"Best Practice and Research Clinical Rheumatology"},{"issue":"9","key":"10.1002\/14651858.CD006687.pub4-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/pch\/16.9.535","article-title":"Pharmacokinetics 101","volume":"16","author":"Ito","year":"2011","journal-title":"Paediatrics & Child Health"},{"key":"10.1002\/14651858.CD006687.pub4-BIB0111|cit111","unstructured":"Lefebvre C Manheimer E Glanville J Chapter 6. Searching for studies. In: Higgins JP, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from handbook.cochrane.org"},{"key":"10.1002\/14651858.CD006687.pub4-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaut.2014.01.020","article-title":"International consensus criteria for the diagnosis of Raynaud's phenomenon","volume":"48-9","author":"Maverakis","year":"2014","journal-title":"Journal of Autoimmunity"},{"issue":"9","key":"10.1002\/14651858.CD006687.pub4-BIB0113|cit113","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1002\/art.10486","article-title":"Measuring disease activity and functional status in patients with scleroderma and Raynaud's phenomenon","volume":"46","author":"Merkel","year":"2002","journal-title":"Arthritis and Rheumatology"},{"key":"10.1002\/14651858.CD006687.pub4-BIB0114|cit114","unstructured":"Phase III study of topical gel for treatment and prevention of Raynaud's phenomenon clinicaltrials.gov\/ct2\/show\/NCT00266669"},{"key":"10.1002\/14651858.CD006687.pub4-BIB0115|cit115","unstructured":"Phase III study of topical gel for treatment and prevention of Raynaud's phenomenon clinicaltrials.gov\/show\/NCT00266669"},{"key":"10.1002\/14651858.CD006687.pub4-BIB0116|cit116","first-page":"1119","article-title":"Raynaud's phenomenon (primary)","volume":"2011","author":"Pope","year":"2011","journal-title":"British Medical Journal Clinical Evidence"},{"issue":"6","key":"10.1002\/14651858.CD006687.pub4-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.autrev.2013.12.001","article-title":"Raynaud's phenomenon: from molecular pathogenesis to therapy","volume":"13","author":"Prete","year":"2014","journal-title":"Autoimmunity Reviews"},{"key":"10.1002\/14651858.CD006687.pub4-BIB0118|cit118","unstructured":"National Library for Health. Clinical Knowledge Summaries. Raynaud's phenomenon cks.library.nhs.uk\/raynauds_phenomenon"},{"key":"10.1002\/14651858.CD006687.pub4-BIB0119|cit119","unstructured":"The Cochrane Collaboration Review Manager Web (RevMan Web) 2019"},{"issue":"2b","key":"10.1002\/14651858.CD006687.pub4-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0002-9343(85)90168-8","article-title":"Treatment of Raynaud's phenomenon with calcium channel blockers","volume":"78","author":"Smith","year":"1985","journal-title":"American Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD006687.pub4-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJMra1507638","article-title":"Raynaud's phenomenon","volume":"375","author":"Wigley","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"10.1002\/14651858.CD006687.pub4-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1002\/art.40457","article-title":"A multicenter study of the validity and reliability of responses to hand cold challenge as measured by laser speckle contrast imaging and thermography: outcome measures for systemic sclerosis-related Raynaud's Phenomenon","volume":"70","author":"Wilkinson","year":"2018","journal-title":"Arthritis and Rheumatology"},{"issue":"2","key":"10.1002\/14651858.CD006687.pub4-BIB0123|cit123","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/clpt.1986.166","article-title":"Double-blind, placebo-controlled study of prazosin in Raynaud's phenomenon","volume":"40","author":"Wollersheim","year":"1986","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"7","key":"10.1002\/14651858.CD006687.pub4-BIB0124|cit124","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006687.pub3","article-title":"Oral vasodilators for primary Raynaud's phenomenon","author":"Stewart","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD006687.pub4-BIB0125|cit125","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006687","article-title":"Oral vasodilators for primary Raynaud's Phenomenon","author":"Vinjar","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD006687.pub4-BIB0126|cit126","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006687.pub2","article-title":"Oral vasodilators for primary Raynaud's phenomenon","author":"Vinjar","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T03:34:14Z","timestamp":1671075254000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD006687.pub4"}},"subtitle":[],"editor":[{"name":"Cochrane Vascular Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,5,17]]},"references-count":126,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd006687.pub4","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,17]]}}}